Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CD44 | P16070 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11491312 | 0.88 | NPC1 (0.52) | NPC1RAB9ACD44ALDH1A1MEN1 | |
| SCHEMBL14863130 | 0.85 | CD44 (0.46) | CD44ALDH1A1MEN1LMNATHRA | |
| SCHEMBL27372303 | 0.84 | ALDH1A1 (0.52) | CD44ALDH1A1MEN1LMNATHRA | |
| SCHEMBL11738897 | 0.83 | TSHR (0.45) | RAB9ACD44ALDH1A1MEN1LMNA | |
| SCHEMBL8207031 | 0.81 | L3MBTL1 (0.51) | NPC1RAB9ACD44MEN1KMT2A | |
| SCHEMBL16268278 | 0.81 | CD44 (0.45) | CD44ALDH1A1MEN1LMNATHRA | |
| SCHEMBL23619640 | 0.81 | ALDH1A1 (0.47) | CD44ALDH1A1MEN1LMNATHRA | |
| SCHEMBL29865634 | 0.81 | KDM4E (0.51) | CD44ALDH1A1MEN1LMNATHRA | |
| SCHEMBL2810333 | 0.79 | CD44 (0.56) | CD44PNMTMAOBP2RX7 | |
| Hydrochloric Acid SCHEMBL2867007 | 0.78 | CD44 (0.54) | CD44PNMTMAOBP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-05 | — | — | US | disclosed |
| EP-2766347-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9079929-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-2766347-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-103987696-A | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO | 2014-08-13 | — | — | CN | disclosed |
| WO-2013056034-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| CN-101501036-B | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA | 2013-04-17 | — | — | CN | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| CN-1817864-A | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2006-08-16 | — | — | CN | disclosed |
| CN-1608052-A | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2005-04-20 | — | — | CN | disclosed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | NPC1 4135/4885RAB9A 634/4885CD44 1897/4885 |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | NPC1 3716/4885RAB9A 2779/4885CD44 4830/4885 |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | NPC1 1203/4885RAB9A 1347/4885CD44 4883/4885 |
| US-20200071277-A1 | PHOTOREACTIVE LIGANDS AND USES THEREOF | CLTB, CRYAB, CRYAA | NPC1 4135/4885RAB9A 634/4885CD44 1897/4885 |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | NPC1 1404/4885RAB9A 2669/4885CD44 4841/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | NPC1 3716/4885RAB9A 2779/4885CD44 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.